United Therapeutics Co. (NASDAQ:UTHR – Get Rating)’s stock price traded down 3.1% during mid-day trading on Thursday following insider selling activity. The company traded as low as $224.15 and last traded at $224.15. 401 shares were traded during trading, a decline of 100% from the average session volume of 571,206 shares. The stock had previously closed at $231.29.Specifically, CEO Martine A. Rothblatt sold 3,000 shares of the stock in a transaction dated Friday, May 27th. The shares were sold at an average price of $231.27, for a total value of $693,810.00. Following the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at approximately $30,065.10. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Paul A. Mahon sold 6,000 shares of the business’s stock in a transaction dated Thursday, March 17th. The shares were sold at an average price of $182.42, for a total transaction of $1,094,520.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 47,000 shares of company stock valued at $9,390,830. 12.10% of the stock is currently owned by insiders.
Several analysts recently commented on UTHR shares. Wedbush raised their target price on United Therapeutics from $236.00 to $263.00 and gave the company an “outperform” rating in a research report on Tuesday, May 24th. JPMorgan Chase & Co. lifted their price objective on shares of United Therapeutics from $225.00 to $238.00 in a research note on Tuesday, May 24th. LADENBURG THALM/SH SH decreased their target price on shares of United Therapeutics from $231.00 to $203.00 and set a “buy” rating for the company in a research report on Friday, February 25th. Zacks Investment Research downgraded shares of United Therapeutics from a “buy” rating to a “hold” rating and set a $175.00 price target on the stock. in a research report on Tuesday, March 1st. Finally, HC Wainwright increased their price objective on shares of United Therapeutics from $248.00 to $255.00 and gave the company a “buy” rating in a report on Tuesday, May 24th. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $236.78.
The firm has a market capitalization of $10.14 billion, a price-to-earnings ratio of 16.01, a PEG ratio of 5.10 and a beta of 0.61. The company has a current ratio of 8.84, a quick ratio of 8.54 and a debt-to-equity ratio of 0.19. The stock has a fifty day moving average of $190.62 and a 200-day moving average of $193.52.
United Therapeutics (NASDAQ:UTHR – Get Rating) last posted its quarterly earnings data on Wednesday, May 4th. The biotechnology company reported $5.03 EPS for the quarter, beating analysts’ consensus estimates of $2.96 by $2.07. United Therapeutics had a net margin of 38.87% and a return on equity of 17.62%. The company had revenue of $461.90 million during the quarter, compared to analyst estimates of $420.02 million. During the same period in the prior year, the firm earned $0.61 earnings per share. The business’s quarterly revenue was up 21.8% on a year-over-year basis. As a group, equities research analysts forecast that United Therapeutics Co. will post 17.23 earnings per share for the current fiscal year.
A number of large investors have recently made changes to their positions in the business. National Bank of Canada FI purchased a new position in shares of United Therapeutics during the fourth quarter valued at $31,000. Sageworth Trust Co of South Dakota acquired a new position in shares of United Therapeutics in the 4th quarter valued at about $32,000. MCF Advisors LLC purchased a new stake in shares of United Therapeutics in the first quarter worth approximately $34,000. C M Bidwell & Associates Ltd. acquired a new stake in shares of United Therapeutics during the third quarter worth approximately $38,000. Finally, James Investment Research Inc. purchased a new position in United Therapeutics during the fourth quarter valued at approximately $41,000. 94.68% of the stock is currently owned by institutional investors.
About United Therapeutics (NASDAQ:UTHR)
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.